An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2019
At a glance
- Drugs IONIS HTTRx (Primary)
- Indications Huntington's disease
- Focus Adverse reactions
- Sponsors Ionis Pharmaceuticals; Roche
- 09 Jan 2019 Planned End Date changed from 1 Dec 2019 to 31 Oct 2019.
- 09 Jan 2019 Planned primary completion date changed from 1 Dec 2019 to 11 Oct 2019.
- 15 Nov 2018 Status changed from recruiting to active, no longer recruiting.